Clinical trial NCT01093677: Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
Official title: A Single-Blind,Randomized,Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Impaired Glucose Tolerance
Lead sponsor: Limerick BioPharma
Sponsor class: INDUSTRY
First posted: 2010-03-26
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance


Eligibility criteria: Inclusion Criteria:

1. Males, age 18-70 years old
2. Measured waist circumference to hip circumference ratio \>0.90
3. Body mass index (BMI) of 27 - 40 kg/m2
4. Screening and Day -1 capillary glucose measurement between 110-160 mg/dL (6.1-8.9 mmol/L) after a 12 hour fast
5. Screening and Day -1 OGTT with a 2 hour post-glucose measurement ≥140 mg/dL (7.8 mmol/L) after a 12 hour fast
6. Screening HbA1c \> 6 and ≤ 7.5%
7. Subjects must be in reasonably good health as determined by pre-study medical history, physical examination, 12-lead ECG, and the following laboratory measures:

   * Electrolytes, ALP, LDH, creatinine, and urea must be within normal range without medication
   * Urinalysis within normal limits
8. Willing to remain in confinement at the clinical study unit for up to 18 days/17 nights and to return to the unit as specified for additional assessments
9. Willing to consume only the food that is provided by the clinical study unit
10. Non-smokers or "social smokers" (defined as fewer than 5 cigarettes per week) willing to abstain from smoking for the duration of study
11. Willing to abstain from alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages
12. Able to read, understand and follow the study instructions
13. Agree to use of two effective methods of contraception

Exclusion Criteria:

1. Allergy to onions or red wine
2. Strict vegetarians (i.e., subjects who do not eat meat, fish, fowl, or dairy)
3. Use of any non-study medication(s) during the study period other than those approved by the Investigator for treatment of an adverse event (AE)
4. Use of chemotherapy agents or history of cancer, other than non-metastatic non-melanoma skin cancer that has been completely excised, within five (5) years prior to the Screening visit
5. Use of any dietary aids or foods known to modulate drug metabolizing enzymes (e.g., St. John's Wort, grapefruit juice) within 4 days of randomization
6. History of bacterial or viral infection requiring treatment with antibiotics or antivirals within 30 days of randomization
7. Difficulty in swallowing oral medications
8. History of seizure disorder
9. Moderate to severe gastro-esophageal reflux disease
10. History of arrhythmia
11. Cognitive or psychiatric disorders, or any other condition that could interfere with compliance with study procedures and/or confinement in a clinical study unit
12. Baseline liver enzymes greater than the upper limit of normal
13. Baseline creatine phosphokinase (CPK) greater than 2.5x the upper limit of normal
14. History of drug or alcohol abuse
15. Use of any other investigational drug within 30 days of randomization or investigational biologic within 180 days of randomization
16. Use of over-the-counter (OTC) medications or nutraceuticals, excluding routine vitamins, within 14 days of randomization or 5 half-lives of the drug, whichever is longer
17. Use of prescription pharmaceuticals within 30 days of randomization
18. Donation and/or receipt of any blood or blood products within 90 days of randomization
19. Current gastrointestinal (GI), renal, hepatic, or coagulant disorder within 12 months of randomization
20. History of peptic or duodenal ulcer or GI bleed
21. Subjects with Gilbert's Syndrome
22. Subjects with positive drug or alcohol screen
23. Subject positive for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody

Primary outcomes:
measure: To evaluate the effect of LIM-0705 on glucose metabolism, lipid metabolism and renal function in subjects with impaired glucose tolerance
timeFrame: approx. 1 month
Secondary outcomes:
measure: Incidence of treatment emergent adverse events and pharmacokinetics of LIM-0705 and its major metabolite
timeFrame: approx. 1 month
Other outcomes:
Locations:
Study officials:
affiliation: Nucleus Network
name: Albert Frauman, MD
role: STUDY_DIRECTOR
References: